CDT Equity (CDT) Short term Debt (2023 - 2024)

CDT Equity's (CDT) quarterly Short term Debt came in at $1.5 million in Q3 2024, up 714.75% on a QoQ basis from $183000.0 in Q2 2024.

CDT Equity (CDT) Short term Debt (2023 - 2024) Analysis & Trends

CDT Equity (CDT) has 2 years of Short term Debt data on file, last reported at $1.5 million in Q3 2024.

Quarterly Short term Debt changed N/A year-over-year to $1.5 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.5 million (changed N/A YoY) and the FY2023 annual result came in at $185000.0, changed N/A from the prior year.
Short term Debt climbed to $1.5 million in Q3 2024, from $183000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $1.5 million in Q3 2024 to a low of $183000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CDT Equity	1.55 Mn	1.55 Mn	-

Download Data